2017 ACVIM Forum Research Abstract Program

This study was a randomized, masked, cross-over PK study. Eight apparently healthy adult cats 6-12 years of age were studied. All cats were healthy as determined by daily clinical observations through a 7 day acclimation period, physical examination, and CBC/serum chemistry. All cats wore Elizabethan collars throughout the course of the study. On Day 0, four cats were treated once with 0.5 mg/kg of 2% MZP applied to the inner pinna of the right ear, and four cats were treated once with 0.5 mg/kg of 2% MZP given orally by syringe to the back of the mouth. On Day 5 the cats crossed over to the opposite treatment. Plasma was collected pre-dose and at 1, 2, 4, 6, 8, 12, 24, 48, 72 and 96 hours after administration and frozen at À20°C prior to shipping and analysis. Plasma mirtazapine concentrations were measured using a validated LC-MS/MS method. PK parameters were calculated using standard methods WinNonlin Professional 5.3. PK parameters were statistically compared between treatments using Wilcoxon Signed Rank test with significance set at P < 0.05.